https://www.selleckchem.com/pr....oducts/Rapamycin.htm
This study reports the MTD, recommended phase 2 dose (RP2D), and preliminary efficacy of alpelisib or buparlisib used in combination with tamoxifen plus goserelin in premenopausal patients with hormone receptor-positive (HR ), HER2-negative (HER2 ) advanced breast cancer (ABC). This study enrolled premenopausal women with HR , HER2 ABC. Patients received tamoxifen (20 mg once daily) and goserelin acetate (3.6 mg every 28 days) with either alpelisib (350 mg once daily; = 16) or buparlisib (100 mg once daily; = 13) in 28-day cycles unti
Like
Comment
Share
